secwatch.observer — SEC 8-K summary
======================================

Issuer:     INSMED Inc (INSM)
CIK:        0001104506
Form:       8-K
Filed at:   2026-10-05T11:01:19+00:00
Accession:  0001140361-26-038529
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Insmed CFO Sara Bonstein to step down October 30; company reaffirms full-year 2026 guidance
--------------------------------------------------------------------------------

- CFO Sara Bonstein will separate from Insmed effective October 30, 2026, and will stay through the Q3 2026 results and the October 29 earnings call.
- Insmed said the transition is not related to any disagreement on accounting practices, financial statements, internal controls or operations.
- Insmed reaffirmed 2026 guidance: BRINSUPRI revenue of $1.25B-$1.40B and ARIKAYCE revenue of $450M-$470M.
- CEO Will Lewis said Insmed raised more than $4.2 billion in capital during Bonstein's nearly seven years as CFO; a search firm is aiding the successor search.
- Q3 2026 financial results will be released October 29, 2026, with a conference call at 8:00 a.m. ET.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1104506/000114036126038529/0001140361-26-038529-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1104506/000114036126038529/ef20083216_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-038529

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer